Staging gallbladder cancer with lymphadenectomy: the practical application of new AHPBA and AJCC guidelines.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
11 2019
Historique:
received: 14 09 2018
revised: 03 03 2019
accepted: 26 03 2019
pubmed: 24 4 2019
medline: 16 7 2020
entrez: 24 4 2019
Statut: ppublish

Résumé

Current guidelines recommend harvesting a total lymph node count (TLNC) ≥6 from portal lymphadenectomy in ≥pT1b gallbladder cancers (GBC) for accurate staging and prognostication. This study aimed to determine nodal yields from portal lymphadenectomy and identify measures to maximize TLNC. We retrospectively reviewed all ≥pT1b GBC which underwent resection with curative intent including portal lymphadenectomy at our specialized HPB center from 2007 to 2017. We compared outcomes of TLNC < 6 and TLNC ≥ 6 cohorts and determined factors predictive of TLNC. Of 92 patients, 20% had a TLNC ≥ 6 (IQR 7-11) and 9% had no nodes found on pathology. Malignant lymphadenopathy was twice as common in TLNC ≥ 6 as TLNC < 6 (p = 0.003) most frequently from portal, cystic and pericholedochal stations. On logistic regression analysis, concomitant liver resection was an independent predictor of higher TLNC [4b/5 wedge resection (OR 0.166, CI 0.057-0.486, p = 0.001) extended hepatectomy (OR 0.065, CI 0.012-0.340, p = 0.001)]; biliary resection and en bloc adjacent organ resection were not. At our center, prior to current guidelines, a TLNC≥6 was not met in 80% undergoing portal lymphadenectomy for ≥ pT1b GBC. To increase nodal yield, future guidelines should consider including additional lymph node stations and incorporation of frozen section analysis.

Sections du résumé

BACKGROUND
Current guidelines recommend harvesting a total lymph node count (TLNC) ≥6 from portal lymphadenectomy in ≥pT1b gallbladder cancers (GBC) for accurate staging and prognostication. This study aimed to determine nodal yields from portal lymphadenectomy and identify measures to maximize TLNC.
METHODS
We retrospectively reviewed all ≥pT1b GBC which underwent resection with curative intent including portal lymphadenectomy at our specialized HPB center from 2007 to 2017. We compared outcomes of TLNC < 6 and TLNC ≥ 6 cohorts and determined factors predictive of TLNC.
RESULTS
Of 92 patients, 20% had a TLNC ≥ 6 (IQR 7-11) and 9% had no nodes found on pathology. Malignant lymphadenopathy was twice as common in TLNC ≥ 6 as TLNC < 6 (p = 0.003) most frequently from portal, cystic and pericholedochal stations. On logistic regression analysis, concomitant liver resection was an independent predictor of higher TLNC [4b/5 wedge resection (OR 0.166, CI 0.057-0.486, p = 0.001) extended hepatectomy (OR 0.065, CI 0.012-0.340, p = 0.001)]; biliary resection and en bloc adjacent organ resection were not.
CONCLUSION
At our center, prior to current guidelines, a TLNC≥6 was not met in 80% undergoing portal lymphadenectomy for ≥ pT1b GBC. To increase nodal yield, future guidelines should consider including additional lymph node stations and incorporation of frozen section analysis.

Identifiants

pubmed: 31010632
pii: S1365-182X(19)30498-8
doi: 10.1016/j.hpb.2019.03.372
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1563-1569

Informations de copyright

Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Natasha L Leigh (NL)

Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai St. Luke's Roosevelt Hospital, 425 West 59th Street, Suite 7B, New York, NY 10019, United States; Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States. Electronic address: Natasha.leigh@mountsinai.org.

Daniel Solomon (D)

Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Daniela Feingold (D)

Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Spiros P Hiotis (SP)

Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Daniel M Labow (DM)

Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai St. Luke's Roosevelt Hospital, 425 West 59th Street, Suite 7B, New York, NY 10019, United States; Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Deepa R Magge (DR)

Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai St. Luke's Roosevelt Hospital, 425 West 59th Street, Suite 7B, New York, NY 10019, United States; Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Umut Sarpel (U)

Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Benjamin J Golas (BJ)

Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai St. Luke's Roosevelt Hospital, 425 West 59th Street, Suite 7B, New York, NY 10019, United States; Mount Sinai Hospital Division of Surgical Oncology, Icahn School of Medicine at Mount Sinai, 19 East 98th Street, Suite 7A, New York, NY 10029, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH